



5.30.035

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	September 9, 2008
Subject:	Fabrazyme	Page:	1 of 4

Last Review Date: March 7, 2025

Fabrazyme

Description

Fabrazyme (agalsidase beta)

Background

Fabry disease is an X-linked genetic disorder of glycosphingolipid metabolism. Deficiency of the lysosomal enzyme α -galactosidase A leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues, starting early in life and continuing over decades. Clinical manifestations of Fabry disease include neuropathy, renal failure, cardiomyopathy, and cerebrovascular accidents. Accumulation of GL-3 in renal endothelial cells may play a role in renal failure (1).

Regulatory Status

FDA-approved indication: Fabrazyme is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease (1).

Fabrazyme contains a boxed warning regarding hypersensitivity reactions including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Prior to Fabrazyme administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Initiate Fabrazyme in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment (1).

The safety and effectiveness of Fabrazyme in pediatric patients less than 2 years of age have not been established (1).

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	September 9, 2008
Subject:	Fabrazyme	Page:	2 of 4

Related policies

Elfabrio, Galafold

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Fabrazyme may be considered **medically necessary** if the conditions indicated below are met.

Fabrazyme may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 2 years of age or older

Diagnosis

Patient must have the following:

Fabry disease

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 2 years

Prior – Approval *Renewal* Limits

Same as above

Rationale

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	September 9, 2008
Subject:	Fabrazyme	Page:	3 of 4

Summary

Fabrazyme is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types. Fabrazyme contains a boxed warning for hypersensitivity reactions including anaphylaxis. The safety and effectiveness of Fabrazyme in pediatric patients less than 2 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Fabrazyme while maintaining optimal therapeutic outcomes.

References

1. Fabrazyme [package insert]. Cambridge, MA: Genzyme Corporation; July 2024.

Policy History

Date	Action
March 2010	Age updated to current package insert recommendations. The safety and efficacy of Fabrazyme were assessed in a multi-national, multi-center, uncontrolled, open-label study in 16 pediatric patients with Fabry disease, ages 8 to 16 years. Patients younger than 8 years of age were not included in clinical studies. The safety and efficacy in patients younger than 8 years of age have not been evaluated. No new safety concerns were identified in pediatric patients in this study, and the overall safety and efficacy profile of Fabrazyme treatment in pediatric patients was found to be consistent with that seen in adults.
September 2011	Annual editorial review and reference update
September 2012	Annual editorial review and reference update
June 2013	Annual editorial review and reference update
September 2014	Annual editorial review and reference update
September 2015	Annual review
September 2016	Annual editorial review Policy number change from 5.08.07 to 5.30.35
December 2017	Annual editorial review
November 2018	Annual review
December 2019	Annual editorial review and reference update. Changed approval duration from lifetime to 2 years
December 2020	Annual review

5.30.035

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	September 9, 2008
Subject:	Fabrazyme	Page:	4 of 4

March 2021	Annual review. Age requirement reduced from 8 years and older to 2 years and older
March 2022	Annual review
March 2023	Annual review. Changed policy number to 5.30.035
September 2023	Annual review and reference update. Per SME, added clinical manifestations of Fabry disease including neuropathy to background section
March 2024	Annual review
March 2025	Annual editorial review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 7, 2025 and is effective on April 1, 2025.